PEDIATRICS Vol. 62 No. 4 October 1978, pp. 605-607
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boyle, R. J.
Right arrow Articles by Oh, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boyle, R. J.
Right arrow Articles by Oh, W.

Transcutaneous P02 Monitoring in Infants With Persistent Fetal Circulation Who Are Receiving Tolazoline Therapy

Robert J. Boyle M.D.1 and William Oh M.D.1

1 Department of Pediatrics, Brown University Program in Medicine, Women and Infants Hospital of Rhode Island Providence, Rhode Island

Tolazoline (Priscoline) hydrochloride has been suggested as an effective pulmonary vasodilator in infants with persistent fetal circulation.1.2 The drug can potentially cause systemic vasodilation, hypotension, and cutaneous flushing. Transcutaneous P02 (TcPO2) monitoring has been shown to be a reliable adjunct in the care of the critically ill neonate.3 Peabody et al.4 have reported that tolazoline adversely affects the correlation of TcPO2 and PaO2 and warned against relying on this technique during the administration of the drug. Since instantaneous TcPO2, monitoring in infants who have persistent fetal circulation and who are receiving tolazoline may be useful, we undertook this investigation to evaluate its reliability.